期刊文献+

维生素K拮抗剂作用机制与钙化风险 被引量:3

下载PDF
导出
摘要 血管钙化与许多疾病相关,包括心肌梗死、脑卒中及糖尿病等。血管钙化的机制比较复杂,如钙化抑制物基质1-羧基谷氨酸(-y—carboxyglutamicacid,Gla)蛋白等的减少或缺失,血管细胞的成骨样分化,钙磷代谢的失衡,凋亡小体的产生等。基质Gla蛋白(matrixGlaprotein,MGP)是一种维生素K依赖性抑制钙化蛋白,其中5个Gla残基与羟基磷灰石具有高度亲和力,可显著抑制钙沉积及羟基磷灰石晶体形成,抑制血管平滑肌细胞向成骨样细胞分化。维生素拮抗剂能够干扰维生素K循环,引起Gla生成障碍,从而阻止了MGP抗钙化蛋白功能的正常发挥,加速血管钙化的发生。
作者 付坤 柳景华
出处 《心肺血管病杂志》 CAS 2013年第6期809-811,共3页 Journal of Cardiovascular and Pulmonary Diseases
基金 国家自然科学基金(81070227) 北京市教育委员会科技计划面上项目(350011120118)
  • 相关文献

参考文献24

  • 1Cai Y,Xu M J,Teng X,et al.Intermedin inhibits vascular calcification by increasing the level of matrix gamma-carboxyglutamic acid protein.Cardiovasc Res,2010,85:864-873.
  • 2Collin-Osdoby P.Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.Circ Res,2004,95:1046-1057.
  • 3Vengrenyuk Y,Kaplan TJ,Cardoso L,et al.Computational stress analysis of atherosclerotic plaques in ApoE knockout mice.Ann Biomed Eng,2010,38:738-747.
  • 4Golub EE.Biomineralization and matrix vesicles in biology and pathology.Semin Immunopathol,2011,33:409-417.
  • 5Zhu D,Mackenzie NC,Farquharson C,et al.Mechanisms and clinical consequences of vascular calcification.Front Endocrinol (Lausanne),2012,3:95.
  • 6Suttie JW.Mechanism of action of vitamin K:synthesis of gamma-carboxyglutamic acid.CRC,1980,8:191-223.
  • 7Parker BD,Bauer DC,Ensrud KE,et al.Association of osteocalcin and abdominal aortic calcification in older women:the study of osteoporotic fractures.Calcif Tissue Int,2010,86:185-191.
  • 8齐永芬,唐朝枢.血管钙化—血管损伤性疾病的共同病理生理基础[J].中南医学科学杂志,2011,39(3):241-245. 被引量:11
  • 9Neve A,Corrado A,Cantatore FP.Osteocalcin:Skeletal and extra-skeletal effects.J Cell Physiol,2013,228:1149-1153.
  • 10Ogawa-Furuya N,Yamaguchi T,Yamamoto M,et al.Serum osteocalcin levels are inversely associated with abdominal aortic calcification in men with type 2 diabetes mellitus.Osteoporos Int,2013,24:2223-2230.

二级参考文献25

  • 1蒋年新,宋杰,徐标.维生素K环氧化物还原酶复合体1基因多态性对华法林维持剂量的影响[J].中华心血管病杂志,2007,35(7):652-654. 被引量:5
  • 2Wadelius M,Pirmohamed M.Pharmacogenetics of warfarin:cur-rent status and future challenges.Pharmacogenomics J,2007,7:99-111.
  • 3Veenstra DL,You JH,Rieder MJ,et al.Association of VitaminK epoxide reductase complex 1(VKORC1)variants with warfa-rin dose in a Hong Kong Chinese patient population.Pharmaco-genet Genomics,2005,15:687-691.
  • 4Lindh JD,Holm L,Andersson ML,et al.Influence of CYP2C9genotype on warfarin dose requirements-a systematic review andMeta-analysis.Eur J Clin Pharmacol,2009,65:365-372.
  • 5Miao L,Yang J,Huang C,et al.Contribution of age,bodyweight,and CYP2C9 and VKORC1 genotype to the anticoagulantresponse to warfarin:proposal for a new dosing regimen in Chinesepatients.Eur J Clin Pharmacol,2007,63:1135-1142.
  • 6Lee MT,Chen CH,Chou CH,et al.Genetic determinants of war-farin dosing in the Han-Chinese population.Pharmacogenomics,2009,10:1905-1919.
  • 7黄盛文,徐湘民.VKORC1和CYP2C9基因型对中国人华法林个体化用药剂量影响的前瞻性研究.南方医科大学,博士学位论文2008.
  • 8吴晓盈,程琼,陈慧.基因多态性对老年房颤患者华法林代谢和药效的影响.硕士学位论文,福建医科大学,2008.
  • 9张亚楠,崔炜.CYP4502C9和VKORC1的基因多态性及其他因素与华法林剂量的相关性研究.硕士学位论文,河北医科大学,2008.
  • 10Gu Q,Kong Y,Schneede J,et al.VKORC1-1639G>A,CYP2C9,EPHX1691A>G genotype,body weight,and age areimportant predictors for warfarin maintenance doses in patientswith mechanical heart valve prostheses in southwest China.Eur JClin Pharmacol,2010,66:1217-1227.

共引文献16

同被引文献3

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部